PHXM — Phaxiam Therapeutics SA Share Price
0.000.00%
Last trade - 00:00- €17.47m
- €20.26m
- €1.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.68 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -65.64% | ||
| Return on Equity | -95.68% | ||
| Operating Margin | -1784.31% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 5.28 | 3.72 | 4.18 | 6.65 | 1.33 | 1.05 | 1.6 | -21.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. It offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
Directors
- Jean-Paul Kress NEC (55)
- Gil Beyen CEO (59)
- Eric Soyer CFO
- Stewart Craig CTO
- Francoise Horand-Phothirath VRD
- Anne-cecile Fumey DHR
- Jerome Bailly OTH
- Jean-Sebastien Cleiftie OTH
- Iman El-Hariry OTH
- Sven Andreasson IND (69)
- Philippe Archinard IND (62)
- Luc Dochez IND (46)
- Martine George IND (72)
- Melanie Rolli IND (48)
- Hilde Windels IND (56)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 21st, 2004
- Public Since
- May 7th, 2013
- No. of Employees
- 51
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 6,074,855
- Address
- 60 avenue Rockefeller, LYON, 69008
- Web
- https://erytech.com/
- Phone
- +33 478744438
- Contact
- Eric Soyer
- Auditors
- KPMG S.A.
Upcoming Events for PHXM
Q1 2024 Phaxiam Therapeutics SA Earnings Call
Phaxiam Therapeutics SA Annual Shareholders Meeting
Phaxiam Therapeutics SA Annual Shareholders Meeting
Q2 2024 Phaxiam Therapeutics SA Earnings Release
Q2 2024 Phaxiam Therapeutics SA Earnings Call
Similar to PHXM
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
FAQ
What is the Phaxiam Therapeutics SA share price?
As of Today at 19:16 UTC, shares in Phaxiam Therapeutics SA are trading at €2.88. This share price information is delayed by 15 minutes.
How has the Phaxiam Therapeutics SA share price performed this year?
Shares in Phaxiam Therapeutics SA last closed at €2.88 and the price had moved by -58.69% over the past 365 days. In terms of relative price strength the Phaxiam Therapeutics SA share price has underperformed the FTSE Global All Cap Index by -62.05% over the past year.
What are the analyst and broker recommendations for Phaxiam Therapeutics SA?
The overall consensus recommendation for Phaxiam Therapeutics SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Phaxiam Therapeutics SA dividend yield?
Phaxiam Therapeutics SA does not currently pay a dividend.
Does Phaxiam Therapeutics SA pay a dividend?
Phaxiam Therapeutics SA does not currently pay a dividend.
When does Phaxiam Therapeutics SA next pay dividends?
Phaxiam Therapeutics SA does not currently pay a dividend.
How do I buy Phaxiam Therapeutics SA shares?
To buy shares in Phaxiam Therapeutics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Phaxiam Therapeutics SA?
As of the previous close price of €2.88, shares in Phaxiam Therapeutics SA had a market capitalisation of €17.47m.
Where are Phaxiam Therapeutics SA shares listed?
Here are the trading details for Phaxiam Therapeutics SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: PHXM
What kind of share is Phaxiam Therapeutics SA?
Based on an overall assessment of its quality, value and momentum Phaxiam Therapeutics SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Phaxiam Therapeutics SA share price forecast for 2024?
The analyst consensus target price for shares in Phaxiam Therapeutics SA is €6.80. That is 136.52% above the last closing price of €2.88.
Analysts covering Phaxiam Therapeutics SA currently have a consensus Earnings Per Share (EPS) forecast of -€1.50 for the next financial year.
What is the trend in the Phaxiam Therapeutics SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Phaxiam Therapeutics SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -45.53%.
As of the last closing price of €2.88, shares in Phaxiam Therapeutics SA were trading -29.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Phaxiam Therapeutics SA PE Ratio?
The Phaxiam Therapeutics SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €2.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Phaxiam Therapeutics SA?
Phaxiam Therapeutics SA's management team is headed by:
- Jean-Paul Kress - NEC
- Gil Beyen - CEO
- Eric Soyer - CFO
- Stewart Craig - CTO
- Francoise Horand-Phothirath - VRD
- Anne-cecile Fumey - DHR
- Jerome Bailly - OTH
- Jean-Sebastien Cleiftie - OTH
- Iman El-Hariry - OTH
- Sven Andreasson - IND
- Philippe Archinard - IND
- Luc Dochez - IND
- Martine George - IND
- Melanie Rolli - IND
- Hilde Windels - IND